GlassScriptPhysician profile
Amanda C Wackt
NPI 1801296108
$1,280.05
in general payments reported to CMS, 2019-2025
14 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $443 · 2024: $428 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $208.72 | 2023-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $165.36 | 2024-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Corium, LLC | $159.87 | 2023-2025 | Azstarys |
| Sanofi Pasteur INC. | $155.49 | 2023-2025 | |
| Glaxosmithkline, LLC. | $118.89 | 2023-2025 | Bexsero, Penmenvy, Rotarix |
| Ars Pharmaceuticals Operations, INC. | $108.30 | 2025 | Neffy |
| Seqirus USA INC | $67.42 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Pfizer INC. | $59.82 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $57.74 | 2023-2024 | Flumist Quadrivalent |
| Sanofi-Aventis U.S. LLC | $53.66 | 2025 | |
| Supernus Pharmaceuticals, INC. | $44.58 | 2023 | Qelbree |
| Collegium Pharmaceutical, INC. | $37.96 | 2025 | Jornay Pm |
| Phadia US INC. | $23.19 | 2023 | Immunocap |
| Biomarin Pharmaceutical INC. | $19.05 | 2024 | Voxzogo 1.2mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wackt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.